Pull to refresh
Logo
Daily Brief
Following Why Sign Up
FDA approves Roche's Enspryng as first at-home thyroid eye disease treatment

FDA approves Roche's Enspryng as first at-home thyroid eye disease treatment

New Capabilities

The IL-6 receptor inhibitor joins Tepezza and Lumvoa with a delivery advantage rivals are racing to match

Today: Roche announces Enspryng approval for TED

Overview

Updated 51 minutes ago

The FDA approved Roche's Enspryng for thyroid eye disease on October 15, the first and only at-home subcutaneous treatment for the condition. Patients or caregivers inject the drug with a prefilled syringe or pen after a healthcare provider's training — no infusion clinic visits.

Enspryng blocks the IL-6 receptor, a new mechanism in a field where Amgen's Tepezza and Viridian's Lumvoa both target IGF-1 receptor signaling instead. The approval follows a priority review and pivotal data showing significant improvement in eye bulging and double vision, regardless of how active or long-standing the disease is.

Why it matters

TED patients now have an at-home treatment that skips infusion clinics, and physicians gain a second mechanism beyond Tepezza and Lumvoa.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

52.9%
Proptosis response rate, SatraGO-2 Enspryng arm
Patients achieving at least 2 mm reduction in eye bulging at week 24, versus 23.4% for placebo.
60.7%
Diplopia improvement rate, SatraGO-2
Patients reporting reduced double vision versus 25.8% for placebo in the active TED population.
$1.9B
Tepezza 2025 sales
Amgen's current TED market leader, which requires intravenous infusion, generated $1.9 billion last year.
258
Patients enrolled in SatraGO phase 3 program
Combined enrollment across the identically designed SatraGO-1 and SatraGO-2 trials in 19 countries.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Levi Garraway
Levi Garraway
Chief medical officer and head of global product development, Roche
Announced the approval in Roche's October 16 media release

Organizations Involved

Roche / Genentech
Roche / Genentech
Pharmaceutical company
Markets Enspryng; received FDA approval for the TED indication

Swiss pharmaceutical giant that developed and now markets Enspryng for thyroid eye disease.
Genentech
Genentech
Biotechnology company, Roche subsidiary
Roche's US commercialization arm for Enspryng

Roche's wholly owned subsidiary that markets Enspryng in the United States.
Chugai Pharmaceutical Co.
Chugai Pharmaceutical Co.
Pharmaceutical company, Roche group member
Developed Enspryng using its proprietary antibody recycling technology

Japanese pharmaceutical company that developed Enspryng and licensed it to Roche.
Amgen Inc.
Amgen Inc.
Biotechnology company
Markets Tepezza, the current TED sales leader; developing subcutaneous formulation

Maker of Tepezza (teprotumumab), the first approved TED therapy, which generated $1.9 billion in 2025 sales.
Viridian Therapeutics
Viridian Therapeutics
Biotechnology company
Markets Lumvoa, approved June 2026; developing subcutaneous alternative

Maker of Lumvoa (veligrotug), the second approved IGF-1 receptor inhibitor for TED.

Timeline

2020 October 2026

6 events Latest: Today
Tap a bar to jump to that date

  1. Roche announces Enspryng approval for TED

    Today Statement

    Roche and Chugai issue media releases announcing the approval and positioning home dosing as a key advantage.

  2. FDA approves Enspryng for thyroid eye disease

    Regulatory Approval

    First at-home subcutaneous treatment approved for TED, based on SatraGO-1 and -2 results.

  3. FDA grants priority review for TED application

    Regulatory

    Accepted Enspryng's supplemental approval application, setting an October 15, 2026 decision date.

  4. Viridian's Lumvoa wins FDA approval

    Competitive Event

    Second IGF-1 receptor inhibitor cleared for TED, approved for both active and chronic disease with shorter infusions.

  5. SatraGO results presented at ASOPRS

    Clinical Data

    Full results from SatraGO-1 and SatraGO-2 shared at the American Society of Ophthalmic Plastic and Reconstructive Surgery symposium.

  6. FDA approves Enspryng for NMOSD

    Regulatory Approval

    First approval for satralizumab, in neuromyelitis optica spectrum disorder, establishing its safety profile.

Scenarios

1

Enspryng overtakes Tepezza as leading TED therapy

Possible Resolves by Oct 15, 2028

Discussed by: Fierce Pharma, which flagged Enspryng's convenience edge over both infusion-based rivals

At-home dosing plus a distinct mechanism could drive rapid adoption, especially among patients with chronic TED who face repeated infusions. If Roche prices competitively and payers cover the drug without heavy prior-authorization hurdles, Enspryng could take meaningful share within two years.

2

Rival subcutaneous treatments erode Enspryng's convenience edge

Likely Resolves by End of 2027

Discussed by: pharmaphorum, which reported both competitors' home-dosing development programs

Amgen has phase 3 results for a subcutaneous Tepezza formulation delivered by on-body injector. Viridian plans to file elegrobart, its subcutaneous candidate, in the US in early 2027. Either approval would end Enspryng's status as the only at-home option and force a competition on price and efficacy.

3

Enspryng sales stay modest despite the convenience advantage

Unlikely Resolves by Feb 15, 2028

Discussed by: Industry observers tracking rare-disease launch trajectories

TED is a niche disease, and Tepezza's $1.9 billion franchise reflects years of established physician and payer relationships. If payers impose prior-authorization requirements or steer patients to familiar infusions, Enspryng's launch could disappoint despite its at-home delivery.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

January 2020

Tepezza's 2020 launch — the first TED therapy

The FDA approved Amgen's teprotumumab (Tepezza), the first drug ever cleared for thyroid eye disease. Before 2020, TED patients had only steroids to control swelling and surgery as a last resort.

Then

Tepezza became the standard of care and generated $1.9 billion in 2025 sales, despite requiring eight intravenous infusions.

Now

The launch proved a single mechanism could transform a disease with no prior drug treatment — and established the market Enspryng now enters.

Why this matters now

Tepezza's trajectory shows how quickly a new TED therapy can become dominant, which is the pattern Roche hopes to repeat with a different mechanism and at-home delivery.

June 2026

Viridian's Lumvoa approval (June 2026)

The FDA approved Viridian's veligrotug (Lumvoa), a second IGF-1 receptor inhibitor. Viridian positioned it as the first drug cleared for both active and chronic TED and shortened infusion times versus Tepezza.

Then

Lumvoa gave TED patients a second option and challenged Tepezza's dominance within the same mechanism class.

Now

The approval signaled that differentiated convenience — shorter infusions, broader disease coverage — would drive competition as the market expanded.

Why this matters now

Lumvoa's launch, months before Enspryng's approval, set the pattern for a market where delivery convenience is a headline battleground.

Sources

(7)
+1
Roche Media Release Genentech News Features Fierce Pharma pharmaphorum Chugai Pharmaceutical Healio Ophthalmology Genentech Press Release